Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
GlycoMimetics (GLYC) has issued an update.
GlycoMimetics, Inc. announced significant findings from its Phase 3 trial of uproleselan, targeting relapsed/refractory acute myeloid leukemia, and held a live webcast to discuss these outcomes. While detailed results were shared, this information is for disclosure purposes and will not be considered officially filed or integrated into prior or future securities filings, unless explicitly stated.
Find detailed analytics on GLYC stock on TipRanks’ Stock Analysis page.
